麻生好正　ASOU YOSHIMASA　アソウ ヨシマサ

研究者情報

研究者情報

• 氏名

  麻生好正, アソウ ヨシマサ

所属

• 内科学(内分泌代謝)(壬生), 教授

研究業績

論文

原著論文
• Circulating CD4+PD-1+ and CD8+PD-1+ T cells are profoundly decreased at the onset of fulminant type 1 diabetes and are restored by treatment, contrasting with CD4+CD25+FoxP3+ regulatory T cells., Iijima T, Kato K, Jojima T, Tomotsune T, Fukushima M, Suzuki K, Aso Y, Diabetes Res Clin Pract, 133, 10-12, 2017年11月

  DOI
• Effect of insulin degludec versus insulin glargine on glycemic control and daily fasting blood glucose variability in insulin-na?ve Japanese patients with type 2 diabetes: I'D GOT trial., Aso Y, Suzuki K, Chiba Y, Sato M, Fujita N, Takada Y, Murano S, Kuroda H, Diabetes Res Clin Pract, 130, 237-243, 2017年08月

  DOI
• Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM), Matsumura M, Nakatani Y, Tanka S, Aoki C, Sagara M, Yanagi K, Suzuki K, Aso Y, Diabetes Ther, 8（4）, 821-827, 2017年08月

  DOI
• Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice, Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, Suzuki K, Kasai K, Aso Y, Atherosclerosis, 261, 44-51, 2017年06月

  DOI
• The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial, Kato K, Suzuki K, Aoki C, Sagara M, Niitani T, Wakamatsu S, Yanagi K, Aso Y, Expert Opin Pharmacother, 18（8）, 743-751, 2017年06月

  DOI
• Evaluation of a Premixed Insulin Analog Suspension in Japanese People with Type 2 Diabetes and the Clinical Importance of Improved Injection Techniques: A Cross-Sectional Pilot Study, Suzuki K, Aoki C, Kato K, Shimizu M, Sakurai S, Yanagi K, Kuroda H, Aso Y, Diabetes Ther, 8（2）, 445-449, 2017年04月

  DOI
• Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index., Aoki C, Suzuki K, Kuroda H, Sagara M, Shimizu M, Kasai K, Aso Y., Nagoya J Med Sci., 79, 9-16, 2017年02月
• Clinical Implication of Plasma Hydrogen Sulfide Levels in Japanese Patients with Type 2 Diabetes., Suzuki K, Sagara M, Aoki C, Tanaka S, Aso Y., Intern Med, 56, 17-21, 2017年01月
• Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes., Jojima T, Tomotsune T, Iijima T, Akimoto K, Suzuki K, Aso Y., Diabetol Metab Syndr., 8, 45, 2016年07月
• Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study., Sagara M, Suzuki K, Aoki C, Tanaka S, Taguchi I, Inoue T, Aso Y., Cardiovasc Diabetol., 15, 76-85, 2016年05月
• Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study., 2. Akiyama Y, Morita-Ohkubo T, Oshitani N, Ohno Y, Aso Y, Inukai T, Kakei M, Kawakami M, Awata T, Katayama S, and Matsuda M, Diabetology International, 7（25）, 25-33, 2016年03月

  DOI
• Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+cells in patients with type 2 diabetes., Aso, Y, Jojima T, Iijima T, Suzuki K, Terasawa T, Fukushima M, Momobayashi M, Hara K, Takebayashi K, Kasai K, Inukai T., Endocrine, 50（3）, 659-664, 2015年12月

  DOI
• Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes., Aso, Y, Fukushima M, Sagara M, Jojima T, Iijima T, Suzuki K, Momobayashi M, Kasai K, Inukai T., Diabetes Res Clin Pract, 110（3）, 250-256, 2015年12月
• Self-awareness of fast eating and its impact on diagnostic components of metabolic syndrome among middle-aged Japanese males and females., Nohara A, Maejima Y, Shimomura K, Kumamoto K, Takahashi M, Akuzawa M, Negishi M, Ishiyama N, Nagano N, Aso Y, Takenoshita S, Shimomura Y., Endocrine Regulation, 49（2）, 91-96, 2015年02月
• Bezafibrate, a peroxisome proliferator-activated receptor α agonist, decreases circulating CD14(+)CD16(+) monocytes in patients with type 2 diabetes., Terasawa T, Aso Y, Omori K, Fukushima M, Momobayashi A, Inukai T, Transl Res., 165, 336-345, 2015年02月
• A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus, Domeki N, Matsumura M, Monden T, Nakatani Y, Aso Y, Diabetes Ther, 5（2）, 403-413, 2014年12月

  DOI
• Greater Efficacy and Improved Endothelial Dysfunction in Untreated Type 2 Diabetes with Liraglutide versus Sitagliptin, Suzuki K, Tanaka S, Aoki C, Kato K, Jojima T, Aso Y, Dokkyo J Med Sci, 41（3）, 211-220, 2014年10月
• The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes, Aso Y, Terasawa T, Kato K, Jojima T, Suzuki K, Iijima T, Kawagoe Y, Mikami S, Kubota Y, Inukai T, Kasai K, Transl Res, 162（5）, 309-316, 2013年11月

  DOI
• Improvement of glycemic control by re-education in insulin injection technique in patients with diabetes mellitus., Nakatani Y, Matsumura M, Monden T, Aso Y, Nakamoto T, Adv Ther, 30（10）, 897-906, 2013年10月
• Hyperparathyroidism caused by a functional parathyroid cyst, Suzuki K, Sakuta A, Aoki C, Aso Y, BMJ Case Rep, 2013, bcr2012008290, 2013年06月

  DOI
• Miglitol, an anti-diabetic drug, inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase, Aoki C, Suzuki K, Yanagi K, Satoh H, Niitani M, Aso Y, J Pharmacol Sci, 120（2）, 121-128, 2012年08月
• Serum level of soluble CD26/DPP-4 predicts the response to sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in patients with type 2 diabetes inadequately controlled by metformin and/or sulfonylurea., Aso Y, Ozeki N, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Shibazaki M, Haruki K, Inukai T, Translational Research, 159, 25-31, 2012年01月
• Spontaneous platelet aggregation evaluated by laser light scatter in patients with type 2 diabetes: Effect of short-term improved glycemic control and adiponectin., Hara K, Omori K, Sumioka Y, Aso Y, Translational Research, 159, 15-24, 2012年01月
• Elevation of serum high molecular weight adiponectin in patients with type 2 diabetes and orthostatic hypotension: association with arterial stiffness and hypercoagulability, Aso Y, Wakabayashi S, Terasawa T, Naruse R, Hara K, Suetsugu M, Takebayashi K, Inukai T, Diabetic Medicine, 29, 80-87, 2012年01月
• 2型糖尿病治療早期におけるリラグルチドの有用性 患者満足度調査も含めて, 鈴木國弘, 田中精一, 青木千枝, 柳一徳, 中野記子, 作田亜有子, 川越宣明, 麻生好正, 笠井貴久男, Prog Med, 32（3）, 701-706, 2012年03月
• CD-1db/db mice: A novel type 2 diabetic mouse model with progressive kidney fibrosis., Mizunuma Yuiko;Kanasaki Keizo;Nitta Kyoko;Nakamura Yuka;Ishigaki Yasuhito;Takagaki Yuta;Kitada Munehiro;Li Shaolan;Liu Haijie;Li Jinpeng;Usui Isao;Aso Yoshimasa;Koya Daisuke, Journal of diabetes investigation, 11（6）, 1470-1481, 2020年11月

  DOIPermalink
• Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes., Aso Yoshimasa;Kase Masato;Sagara Masaaki;Sakurai Shintaro;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, The American journal of the medical sciences, 360（3）, 261-267, 2020年

  DOIPermalink
• Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis., Sakurai Shintaro;Jojima Teruo;Iijima Toshie;Tomaru Takuya;Usui Isao;Aso Yoshimasa, Journal of diabetes and its complications, 34（11）, 107703, 2020年

  DOIPermalink
• No Negative Impact of a National State of Emergency by COVID-19 Outbreak on Hemoglobin A1c Levels in Patients With Type 2 Diabetes Living in Semi-Rural Japan., Aso Yoshimasa;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, The American journal of the medical sciences, 362（1）, 104-105, 2021年03月31日

  DOIPermalink
• Serum high-molecular-weight adiponectin and response to dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease., Aso Yoshimasa;Sagara Masaaki;Niitani Takafumi;Kato Kanako;Iijima Toshie;Tomaru Takuya;Jojima Teruo;Usui Isao, Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 69（7）, 1324-1329, 2021年05月21日

  DOIPermalink
• Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors., Iijima Toshie;Hosonuma Soichiro;Kurai Hidetaka;Kajitani Hayato;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, International journal of clinical practice, 75（11）, e14732, 2011年08月19日

  DOIPermalink
• Serum levels of soluble dipeptidyl peptidase-4 in type 2 diabetes are associated with severity of liver fibrosis evaluated by transient elastography (FibroScan) and the FAST (FibroScan-AST) score, a novel index of non-alcoholic steatohepatitis with significant fibrosis., Sagara Masaaki;Iijima Toshie;Kase Masato;Kato Kanako;Sakurai Shintaro;Tomaru Takuya;Jojima Teruo;Usui Isao;Aso Yoshimasa, Journal of diabetes and its complications, 35（5）, 107885, 2021年02月06日

  DOIPermalink
• Empagliflozin increases plasma levels of campesterol, a marker of cholesterol absorption, in patients with type 2 diabetes: Association with a slight increase in high-density lipoprotein cholesterol., Jojima Teruo;Sakurai Shintaro;Wakamatsu Sho;Iijima Toshie;Saito Masahiro;Tomaru Takuya;Kogai Takahiko;Usui Isao;Aso Yoshimasa, International journal of cardiology, 331, 243-248, 2021年02月05日

  DOIPermalink

総説論文
• Intensive risk factor management and cardiovascular autonomic neuropathy in type 2 diabetes in the Action to Control Cardiovascular Risk in Diabetes trial: A post-hoc analysis., Aso Yoshimasa, Journal of diabetes investigation, 12（8）, 1316-1318, 2021年05月19日

  DOIPermalink

症例報告
• Genetic alteration of ARMC5 in a patient diagnosed with meningioma and primary macronodular adrenal hyperplasia: a case report., Jojima Teruo;Kogai Takahiko;Iijima Toshie;Kato Kanako;Sagara Masaaki;Kezuka Atsumi;Kase Masato;Sakurai Shintaro;Akimoto Kazumi;Sakumoto Junko;Namatame Takashi;Ueki Keisuke;Hishinuma Akira;Kamai Takao;Usui Isao;Aso Yoshimasa, European journal of endocrinology, 183（6）, K7-K12, 2020年12月

  DOIPermalink
• Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitor showing unfavorable outcomes despite immediate discontinuation of medication., Shinohara Yasutake;Iijima Toshie;Sakurai Shintaro;Jojima Teruo;Ohira Eriko;Hayashi Shujiro;Usui Isao;Igawa Ken;Aso Yoshimasa, Clinical case reports, 8（10）, 2007-2012, 2020年10月

  DOIPermalink
• A case of hypoparathyroidism, deafness, and renal dysplasia (HDR) syndrome with a novel frameshift variant in GATA3, p.W10Cfs40, lacks kidney malformation., Kishi Haruka;Jojima Teruo;Kogai Takahiko;Iijima Toshie;Ohira Eriko;Tanuma Dai;Konno Sachiyo;Kato Kanako;Kezuka Atsumi;Akimoto Kazumi;Sakumoto Junko;Hishinuma Akira;Tomaru Takuya;Makita Noriko;Usui Isao;Aso Yoshimasa, Clinical case reports, 8（12）, 2619-2624, 2020年12月

  DOIPermalink
• Updates in diabetic neuropathy: A call for new diagnostic and treatment approaches., Aso Yoshimasa, Journal of diabetes investigation, 13（3）, 432-434, 2022年

  DOIPermalink
• Symptomatic hypocalcemia after treatment for hyperthyroidism in a woman with chromosome 22q11.2 deletion syndrome complicated by Graves' disease: longitudinal changes in the number of subsets of CD4 and CD8 lymphocytes after thyroidectomy., Iijima Toshie;Jojima Teruo;Hosonuma Soichiro;Ohhira Eriko;Tomaru Takuya;Kogai Takahiko;Usui Isao;Aso Yoshimasa, Endocrine journal, 68（10）, 1187-1195, 2021年10月28日

  DOIPermalink

その他
• Primary Adrenal Leiomyosarcoma in an Aged Japanese Woman: A Rare Case Report, Aoki C, Tanaka S, Suzuki K, Sagara M, Aso Y., J Clin Case Rep, 7, 935, 2017年03月

  DOI
• Postprandial Reactive Hypoglycemia Treated with a Low-dose Alphaglucosidase Inhibitor: Voglibose May Suppress Oxidative Stress and Prevent Endothelial Dysfunction., Suzuki K, Katsura D, Sagara M, Aoki C, Nishida M, Aso Y., Intern Med, 55, 949-953, 2016年08月
• Insulinoma in a patient with chronic renal failure due to type 2 diabetes mellitus treated effectively with diazoxide, Shimizu M, Suzuki K, Tsuchida K, Kojima M, Hiraishi H, Aso Y, Intern Med., 54, 621-625, 2015年06月
• A case in which water intoxication due to excessive water ingestion did not inhibit the secretion of arginine vasopressin., Ishibashi S, Kamisasanuki T, Morita K, Takebayashi K, Aso Y, Ikegami K, Inukai T, Dokkyo J Med Sci, 39, 77-80, 2012年01月
• 脱毛症に対するプレドニゾロン投与を漸減，中止後に発症したコルチコステロイド離脱症候群の1例, 石橋正太、竹林晃三、森田公夫、麻生好正、犬飼敏彦, 埼玉県医学会雑誌, 46, 387-390, 2012年10月
• 自律神経障害の病態と対策., 麻生好正, 糖尿病性合併症, 26, 62-66, 2012年06月
• 糖尿病治療薬 ピオグリタゾン. 最新臨床糖尿病学(上)., 麻生好正, 日本臨牀, 70(S3), 620-626, 2012年04月

講演・口頭発表等

• Effects of sitagliptin versus mitiglinide on insulin, proinsulin, glucagons and GLP-1 response after oral glucose load: A randomized, cross-over study., 23. Matsuda M, Morita T, Oshitani N, Akiyama Y, Oono Y, Aso Y, Inukai T, Kakei M, Kawakami M, Awata T, Katayama S, 2012年06月, ポスター発表, American Diabetes Association, 国際会議
• Serum Level of Soluble CD26/DPP-4 Predicts the Response to Sitagliptin, a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and/or Sulfonylurea., Aso Y, Kasai K, Inukai T, 2012年06月, ポスター発表, American Diabetes Association, 国際会議
• リラグルチドは副交感神経活性を抑制して心拍数を増加させる; 24時間心拍変動パワースペクトル解析を用いた検討, 原健二、麻生好正、小松孝昭、中町隆史、酒井良彦、高柳寛、笠井貴久男、犬飼敏彦:, 2012年11月, 口頭発表（一般）, 第27回日本糖尿病合併症学会, 国内会議
• インクレチン関連薬の心血管系への期待, 麻生好正, 2012年05月, その他, 第40回日本心血管インターベンション治療学会関東甲信越地方会, 国内会議
• 降圧不十分な高血圧患者に対するロサルタン/チアジド配合剤の降圧効果と代謝系に関する検討: 埼玉ELUCIDATE研究2報, 原 健二、麻生好正、寺沢智子、成瀬里香、竹林晃三、犬飼敏彦, 2012年05月, 口頭発表（一般）, 第55回日本糖尿病学会年次学術集会, 国内会議
• 新しい糖尿病治療と神経障害, 麻生好正, 2012年03月, シンポジウム・ワークショップパネル（公募）, 第46回糖尿病学の進歩, 国内会議
• 糖尿病治療の最前線－インクレチンアップデート－, 麻生好正, 2012年03月, その他, 第12回日本内分泌学会関東甲信越支部学術集会, 国内会議

公的助成金（競争的資金）

• 糖尿病患者におけるMuse細胞の機能変化に関する探索的細胞疫学研究, 科学研究費助成事業(獨協医科大学, 東北大学, 獨協医科大学, 獨協医科大学, 獨協医科大学, 獨協医科大学, 獨協医科大学), 小橋 元, 出沢 真理, 春山 康夫, 麻生 好正, 杉本 博之, 内山 浩志, 高山 英士, 2023年06月30日 - 2026年03月31日

教育活動

教育内容・方法の工夫（教育評価含む）

• 教授, 2000年04月, 第3学年 糖尿病(分類、成因、診断)：90分 糖尿病と合併症：90分 糖尿病と治療：90分 先端巨大症と下垂体性巨人症、高プロラクチン血症と無月経・乳汁漏出症候群:90分 下垂体機能低下症：90分 第5学年 BSLクルズス：肥満症とメタボリックシンドローム：60分（2週に1回） BSL：病棟カンファレンス：90分（2週に1回） 第6学年 集中講義 糖尿病(1)：90分 糖尿病(2)：90分